近日，诺和诺德宣布，减重版司美格鲁肽注射液(商品名：诺和盈)心血管适应症上市申请获得中国国家 药品监督管理局(NMPA)批准，适用于降低已确诊为心血管疾病且BMI≥27kg/m2成人患者的主要心血管 不良事件的风险，成为国内首个获批心血管适应症的GLP-1类减重药。 ...

Group 1: Pharmaceutical and Health Sector - The weight-loss version of semaglutide injection (brand name: Nuoheying) has received approval from the National Medical Products Administration (NMPA) in China for cardiovascular indications, aimed at reducing the risk of major cardiovascular adverse events in adults with diagnosed cardiovascular disease and BMI ≥ 27 kg/m², making it the first GLP-1 weight-loss drug approved for cardiovascular indications in the country [1] - Zhiyuan Robotics expects to achieve sales revenue exceeding 1 billion yuan this year, with a projected shipment of 5,000 robots, and anticipates maintaining several-fold growth in both shipment volume and sales revenue in the coming years [1] Group 2: Technology and Automotive Sector - Uber has announced a collaboration with Baidu to launch a pilot project for autonomous taxis in the UK, following similar tests initiated by Waymo in London [1] - Changan Automobile has received the first official license plate for L3-level autonomous driving, marking a significant milestone in the development of autonomous vehicle technology in China [5] Group 3: Investment and Financing - ZhiYuan Pharmaceutical has completed nearly 300 million yuan in Pre-IPO financing, led by Innovation Works, with participation from other institutions [6] Group 4: Consumer Electronics and AI - Chasing Technology has launched the world's first AI health glasses, which monitor health indicators such as heart rate, blood oxygen, and body temperature, and generate personalized health plans using a self-developed health model [7] - Alibaba has introduced the Qwen-Image-Layered image generation model, which allows images to be "decomposed" into multiple layers for independent manipulation without affecting other content [8] Group 5: Robotics and Rental Services - The first open robot rental platform, "Qingtian Rental," has been launched in Shanghai, covering over 50 core cities and more than 600 service providers, with rental prices ranging from 200 yuan to over 10,000 yuan [9]

（文章来源：第一财经） 12月22日，减重版司美格鲁肽注射液（商品名：诺和盈）心血管适应症上市申请获得中国国家药品监督 管理局（NMPA）批准，适用于降低已确诊为心血管疾病且BMI≥27kg/m2成人患者的主要心血管不良事 件的风险，成为国内首个获批心血管适应症的GLP-1类减重药。 ...